ES2384980T3 - Derivados de tetrahidroquinolina sustituidos en 4 con cicloalquilo y su uso como medicamentos - Google Patents

Derivados de tetrahidroquinolina sustituidos en 4 con cicloalquilo y su uso como medicamentos Download PDF

Info

Publication number
ES2384980T3
ES2384980T3 ES05820528T ES05820528T ES2384980T3 ES 2384980 T3 ES2384980 T3 ES 2384980T3 ES 05820528 T ES05820528 T ES 05820528T ES 05820528 T ES05820528 T ES 05820528T ES 2384980 T3 ES2384980 T3 ES 2384980T3
Authority
ES
Spain
Prior art keywords
compound
formula
inhibitors
salts
protecting group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05820528T
Other languages
English (en)
Spanish (es)
Inventor
Hilmar Bischoff
Heike Gielen-Haertwig
Volkhart Li
Carsten Schmeck
Michael Thutewohl
Alexandros Vakalopoulos
Olaf Weber
Martina Wuttke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004060997A external-priority patent/DE102004060997A1/de
Priority claimed from DE102004061000A external-priority patent/DE102004061000A1/de
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of ES2384980T3 publication Critical patent/ES2384980T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES05820528T 2004-12-18 2005-12-15 Derivados de tetrahidroquinolina sustituidos en 4 con cicloalquilo y su uso como medicamentos Expired - Lifetime ES2384980T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102004060997 2004-12-18
DE102004060997A DE102004060997A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004061000A DE102004061000A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004061000 2004-12-18
PCT/EP2005/013490 WO2006063828A1 (de) 2004-12-18 2005-12-15 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente

Publications (1)

Publication Number Publication Date
ES2384980T3 true ES2384980T3 (es) 2012-07-16

Family

ID=35841894

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05820528T Expired - Lifetime ES2384980T3 (es) 2004-12-18 2005-12-15 Derivados de tetrahidroquinolina sustituidos en 4 con cicloalquilo y su uso como medicamentos

Country Status (27)

Country Link
US (2) US8124775B2 (enExample)
EP (1) EP1828137B1 (enExample)
JP (1) JP5132317B2 (enExample)
KR (1) KR20070090248A (enExample)
AR (1) AR055011A1 (enExample)
AT (1) ATE555097T1 (enExample)
AU (1) AU2005315770B2 (enExample)
BR (1) BRPI0519602A2 (enExample)
CA (1) CA2591397A1 (enExample)
CU (1) CU23452B7 (enExample)
CY (1) CY1112887T1 (enExample)
DK (1) DK1828137T3 (enExample)
DO (1) DOP2005000259A (enExample)
ES (1) ES2384980T3 (enExample)
GT (1) GT200500377A (enExample)
IL (1) IL184008A (enExample)
MA (1) MA29100B1 (enExample)
MX (1) MX2007007188A (enExample)
NO (1) NO20073146L (enExample)
PE (1) PE20060767A1 (enExample)
PL (1) PL1828137T3 (enExample)
PT (1) PT1828137E (enExample)
RU (1) RU2393151C2 (enExample)
SI (1) SI1828137T1 (enExample)
TW (1) TW200635900A (enExample)
UY (1) UY29276A1 (enExample)
WO (1) WO2006063828A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005324127A1 (en) * 2004-12-18 2006-07-13 Bayer Healthcare Ag (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors
DE102006012548A1 (de) * 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
ATE520696T1 (de) * 2008-03-05 2011-09-15 Boehringer Ingelheim Int Tricyclische pyridinderivate, solche verbindungen enthaltende medikamente, ihre verwendung und verfahren zu ihrer herstellung
MA34007B1 (fr) 2010-02-19 2013-02-01 Boehringer Ingelheim Int Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation
US9187450B2 (en) * 2010-07-09 2015-11-17 Daiichi Sankyo Company, Limited Substituted pyridine compound
WO2012110599A1 (en) 2011-02-17 2012-08-23 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
US9150583B2 (en) 2011-08-17 2015-10-06 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
US9321747B2 (en) 2012-01-06 2016-04-26 Daiichi Sankyo Company, Limited Acid addition salt of substituted pyridine compound
WO2016016157A1 (en) 2014-07-30 2016-02-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4128681A1 (de) * 1991-08-29 1993-03-04 Bayer Ag Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DE19704244A1 (de) 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
MA24643A1 (fr) * 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
DE19935966A1 (de) 1999-07-30 2001-02-01 Bayer Ag Verfahren zur Reduktion von Ketoalkoholen
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10250687A1 (de) 2002-10-31 2004-05-13 Bayer Ag 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung
AU2005324127A1 (en) * 2004-12-18 2006-07-13 Bayer Healthcare Ag (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors

Also Published As

Publication number Publication date
PE20060767A1 (es) 2006-09-10
IL184008A0 (en) 2007-10-31
US20080255068A1 (en) 2008-10-16
GT200500377A (es) 2006-11-09
MX2007007188A (es) 2007-08-14
AU2005315770B2 (en) 2011-12-08
DOP2005000259A (es) 2006-11-15
KR20070090248A (ko) 2007-09-05
ATE555097T1 (de) 2012-05-15
AR055011A1 (es) 2007-08-01
IL184008A (en) 2012-03-29
BRPI0519602A2 (pt) 2009-02-25
JP5132317B2 (ja) 2013-01-30
CY1112887T1 (el) 2016-04-13
TW200635900A (en) 2006-10-16
EP1828137B1 (de) 2012-04-25
PL1828137T3 (pl) 2012-09-28
EP1828137A1 (de) 2007-09-05
AU2005315770A1 (en) 2006-06-22
MA29100B1 (fr) 2007-12-03
CU23452B7 (es) 2009-12-01
NO20073146L (no) 2007-09-18
UY29276A1 (es) 2006-07-31
PT1828137E (pt) 2012-07-04
RU2393151C2 (ru) 2010-06-27
SI1828137T1 (sl) 2012-08-31
WO2006063828A1 (de) 2006-06-22
US8124775B2 (en) 2012-02-28
US20120142728A1 (en) 2012-06-07
CA2591397A1 (en) 2006-06-22
DK1828137T3 (da) 2012-07-23
RU2007127127A (ru) 2009-01-27
JP2008524145A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
ES2326326T3 (es) Compuestos y procedimientos para tratar la dislipidemia.
CA2209825C (en) Heterocyclic-fused pyridines
WO2021129824A1 (zh) 新型K-Ras G12C抑制剂
US20120142728A1 (en) Chemical compound and its use
US20060069112A1 (en) 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein
US20080194609A1 (en) Chemical Compound and Its Use
KR20040111445A (ko) 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
HUP0102307A2 (hu) Biszpidinszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierjeik
HK1250986A1 (en) Substituted pyridine derivatives useful as c-fms kinase inhibitors
CN109422737A (zh) 咪唑酮类雄激素受体拮抗剂、其制备方法和用途
US5198434A (en) Angiotensin ii antagonizing fused pyridinyloxy containing derivatives
US20050222418A1 (en) Novel tyloindicines and related processes, pharmaceutical compositions and methods
SK104099A3 (en) 2-amino substituted pyridines for use in the treatment of arteriosclerosis and hyperlipoproteinaemia
CN102212056A (zh) 新的双环喹诺酮类化合物
CN101124206B (zh) 4-环烷基取代的四氢喹啉衍生物及其作为药物的用途
JP7688242B1 (ja) ３－フェニルプロピルアミン誘導体
HK1117832A (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
TW202448857A (zh) 含有芳香二並環的化合物
DE102004061001A1 (de) Chemische Verbindung und ihre Verwendung
DE102004061002A1 (de) Chemische Verbindung und ihre Verwendung
DE102004061003A1 (de) Chemische Verbindung und ihre Verwendung